1 Through
proof and simulation, we determine which coding schemes
2 hat digestibility generally increased during
proofing and decreased during baking.
3 We first discuss two kinds of 'evolution-
proof'
antibiotic.
4 stem relies not only on theoretical security
proofs,
but also on how closely the physical system matc
5 The
proofs exploit two recent approaches.
6 of the Illumina array version and is future
proof for newer Illumina array designs.
7 of this study is the lack of histopathologic
proof in most patients.
8 eters that were monitored included alcoholic
proof,
l-lactic acid content, glucose+fructose and aceti
9 tem's stiffness k and the gap x2 between the
proof mass and reverse constraint blocks have significan
10 hat in the designed inertial microswitch the
proof mass weight G, the whole system's stiffness k and
11 trap placement, targeted cleaning, allergen-
proof mattress and pillow encasements, and portable air
12 This study provides direct
proof of a biologically mediated mechanism of volatile e
13 rface of the eye is also a mucosal site, but
proof of a living, resident ocular microbiome remains el
14 This is the first structural and functional
proof of a supramolecular ligand targeting a PPI interfa
15 Here, we give a simple
proof of a theorem: In generalized KS theory (GKS), the
16 been challenging to demonstrate experimental
proof of causality of these risk alleles for renal disea
17 We provide
proof of concept data by profiling 60 drugs on 68 acute
18 er, these new findings provide a preclinical
proof of concept defining C1572 as a promising therapeut
19 This
proof of concept developed herein holds immense promise
20 e-shaped gold particles were fabricated as a
proof of concept experiment.
21 riptional complex and provides rationale and
proof of concept for a combinatorial therapeutic attack
22 This work provides a
proof of concept for a general strategy to use nanohoops
23 Therefore, DPM-1001 represents a
proof of concept for a new approach to therapeutic inter
24 Our studies offer a preclinical
proof of concept for a strategy of cotargeting the EGFR
25 As
proof of concept for anti-TRBC immunotherapy, we develop
26 gnosis in TNBC, and they offer a preclinical
proof of concept for combining CDK7 and BCL-2/BCL-XL inh
27 Our results offer a preclinical
proof of concept for CRLX101 as a modality to improve th
28 ollectively, our results offer a preclinical
proof of concept for ERK5 as a target to enhance T-cell
29 Overall, our results offer preclinical
proof of concept for H3B-6527 as a candidate therapeutic
30 Our results offer
proof of concept for identifying novel cancer risk loci
31 ificance: These findings offer a preclinical
proof of concept for immunotherapeutic targeting of an e
32 Our findings offer a preclinical
proof of concept for immunotherapeutic targeting of TEM8
33 ession in microbial and plant hosts provided
proof of concept for metabolic engineering of pseudolara
34 Our findings offer a preclinical
proof of concept for small-molecule therapies to target
35 e Golgi organizational states and provides a
proof of concept for the classification of drugs and gen
36 Taken together, these results provide
proof of concept for the development of liver-targeted m
37 These findings provide
proof of concept for the development of small molecule i
38 Together, our results offer a preclinical
proof of concept for the low-dose use of isoform-specifi
39 In this study, we provide preclinical
proof of concept for the role of a proinflammatory CXCL1
40 ollectively, our results offer a preclinical
proof of concept for the use of anti-Jagged1/2 to reprog
41 ollectively, our results offer a preclinical
proof of concept for the use of protein myristoylation i
42 cer cell migration and provide a preclinical
proof of concept for their candidacy as targets to treat
43 nction for CD44V6 in lung fibrosis and offer
proof of concept for therapeutic targeting of CD44V6 in
44 The
proof of concept is shown by using polypyrrole (PPy) fil
45 This first
proof of concept may ultimately be applicable to geofenc
46 To evaluate the
proof of concept of an intervention to teach surgeons to
47 These results provide a
proof of concept of systemic antitumor activity after in
48 This work shows a
proof of concept of the use of monodisperse Si and C nan
49 The
proof of concept of utilizing a microfluidic dielectroph
50 F6P-biosensor is a very promising
proof of concept required for the design of a carbohydra
51 Proof of concept studies of tissue phantoms yielded a me
52 Proof of concept studies were performed to detect saliva
53 This
proof of concept study demonstrates that bacterial flora
54 This
proof of concept study demonstrates that pericardial res
55 ed, allowing for the initiation of a Phase-2
proof of concept study.
56 Our findings provide a preclinical
proof of concept supporting the initiation of a clinical
57 Conclusion This study provides
proof of concept that a machine learning model can be ap
58 We have also provided
proof of concept that blocking 12-HETE production is a p
59 These inhibitors provide
proof of concept that both sides of DENV protease active
60 This is a decisive
proof of concept that cancer cells' malignant behaviour
61 These findings provide a
proof of concept that introducing gut bacteria to a herb
62 This study shows
proof of concept that LAIVs boost preexisting, cross-rea
63 Our data provide
proof of concept that single-particle EM can be used to
64 Proof of concept that such proteins can be detected with
65 This study is the first
proof of concept that targeting a lncRNA to transcriptio
66 Collectively, these data provide
proof of concept that targeting thrombin or fibrin(ogen)
67 peutic mechanisms were undefined and in vivo
proof of concept was limited.
68 As a
proof of concept we exposed growing colonies of Escheric
69 As a
proof of concept, 61,913 protein-protein interactions we
70 As
proof of concept, a photo-cross-linkable derivative of c
71 As a
proof of concept, a reversible label-free glutathione-S-
72 As a
proof of concept, a time resolved fluorescence based san
73 As a
proof of concept, amplification of a gene specific to a
74 n silicon and transparent glass surfaces: as
proof of concept, clusters of either one, two, or three
75 As
proof of concept, copper(II) in aqueous samples was conv
76 As
proof of concept, cultured renal epithelial cells were e
77 As
proof of concept, Fogarty et al. (2017) used CRISPR/Cas9
78 Here, as a
proof of concept, genetically engineered BLNs, which dis
79 hen deployed on novel experimental data as a
proof of concept, illustrating the recruitment of LAT to
80 Further, as a
proof of concept, it is demonstrated that the DNF can de
81 d as the best candidate and to establish the
proof of concept, its ability to enhance Neph1-CD and ZO
82 As
proof of concept, Nd/Sm and Nd/Dy are used as binary mod
83 As a preclinical
proof of concept, specific tumor uptake, pharmacokinetic
84 As a
proof of concept, the biodistribution of (89)Zr-Df-pembr
85 As a
proof of concept, the development of dual-membrane-coate
86 As a
proof of concept, the Janus particle-derived catalyst ca
87 As a
proof of concept, this approach shows that stochastic mo
88 As
proof of concept, we apply the theory for the investigat
89 As
proof of concept, we demonstrate that our mouse model pe
90 As an initial
proof of concept, we developed stepwise multiple linear
91 As a
proof of concept, we employed sUHR to determine the lipi
92 In this
proof of concept, we generate and sequence six sciHi-C l
93 Moreover, as a
proof of concept, we include the experimental validation
94 As
proof of concept, we mutagenized a selected region withi
95 As a
proof of concept, we performed a biochemical characteriz
96 sing optical sensing of chloramphenicol as a
proof of concept, we show here that a GFP variant engine
97 As a
proof of concept, we target the ACT1 promoter of the mod
98 As a
proof of concept, we translated our murine data to the t
99 As a
proof of concept, wild-type (ATCC 29212) and vancomycin-
100 validating these assays and ultimately as a "
proof of cure."
101 eferred over others lacking optimization and
proof of efficacy and safety.
102 xpressed at high levels within 1 week, and a
proof of efficient function analysis is shown using the
103 e the phenotype, and genetic or experimental
proof of gain or loss of function in select cases has cl
104 utes to low agonist efficacy, and presents a
proof of mechanism that relocating deltaR improves effic
105 e demonstrate the efficacy of our methods in
proof of principle experiments and application to real w
106 Here, we present
proof of principle experiments of an optical gating conc
107 ases of engineered gene drives due to recent
proof of principle experiments with the CRISPR-Cas9 syst
108 Here we provide a
proof of principle for a novel two-pronged modality refe
109 This study provides the first
proof of principle for an epigenetics-based therapy for
110 ully reconstruct the biliary tree, providing
proof of principle for organ regeneration using human pr
111 This study provides
proof of principle for the application of targeted next-
112 to act against intracellular Mtb, providing
proof of principle for the efficacy of a "release and ki
113 Proof of principle for the potential of scanning LC-FAIM
114 replacement for type 1 diabetes and provide
proof of principle for therapeutic cloning combined with
115 Proof of principle for this therapeutic approach was dem
116 Proof of principle of in vivo targeting of human islets
117 vo In summary, this study provides the first
proof of principle of small-molecule-mediated interferen
118 These
proof of principle results open a pathway for directing
119 A
proof of principle study using F/R incorporated into lip
120 This study provides additional
proof of principle that an apelin receptor agonist may b
121 These results provide a
proof of principle that can inform prospective vaccine d
122 Our work provides
proof of principle that chemotherapy paired with an "eco
123 Overall, our studies represent a clear
proof of principle that MT-Hec1-interacting compounds ma
124 It provides
proof of principle that Skp2 targeting is a promising ap
125 We provide
proof of principle that small molecules that target the
126 This also provides a
proof of principle that suboptimal CD8 T cell in old org
127 CRF-overexpressing (CRF-OE) mice to test the
proof of principle that when CRF is in excess, sex-biase
128 sease susceptibility gene and demonstrate in
proof of principle the utility of induced neuron-based m
129 in recent years from theoretical to clinical
proof of principle with the publication of a first-in-ma
130 As
proof of principle, a range of different shapes, alignme
131 As a
proof of principle, a selected reaction monitoring (SRM)
132 As a
proof of principle, PLSR was used to build soil-bacteriu
133 As a
proof of principle, we acquired 4D (H)COCANH, (H)CACONH,
134 As
proof of principle, we apply HiHiMap to measure the leve
135 As
proof of principle, we apply this approach to interrogat
136 As
proof of principle, we assembled genomes of the pigeon (
137 As a
proof of principle, we demonstrate the capability of thi
138 As a
proof of principle, we demonstrated correlation of the h
139 nting with symptoms of long-QT syndrome as a
proof of principle, we demonstrated that commercially av
140 As
proof of principle, we demonstrated that inactivation of
141 As a
proof of principle, we predict and measure the gap openi
142 As a
proof of principle, we used this new "nanomapping" metho
143 As a
proof of principle, we were able to simultaneously inact
144 miR-430 in developing zebrafish embryos as a
proof of principle.
145 ntrary to previous reports, we have found no
proof of Rb or K incorporation into the 3D perovskite la
146 rtainty for the Brighton Collaboration, with
proof of recent ZIKV infection and negative screening fo
147 ation (3NLSE) domain, and provides a further
proof of the computational abilities of the scheme.
148 As
proof of the concept, the success of the method was demo
149 etical advances, we lack direct experimental
proof of the validity of these widely used control princ
150 gnetic properties, we provide an alternative
proof of validity of these thermal For each individual s
151 ade of rationally designed DNA molecules are
proofs of concept for embedding control within complex m
152 Meanwhile, recent discoveries provide
proofs of principle for breakthroughs in a family of res
153 This
proof-
of-concept analysis demonstrates that unsupervised
154 Here we present a
proof-
of-concept application for the rational design of
155 In a
proof-
of-concept application in organocatalysis, the dia
156 As a
proof-
of-concept application, the obtained ultrathin COF
157 ative stress mechanisms in TBI and provide a
proof-
of-concept approach to improve acute TBI managemen
158 e present experimental results comparing two
proof-
of-concept ballast molecules, and show that the ba
159 scharged MnO2 could be recovered, enabling a
proof-
of-concept biobattery/supercapacitor hybrid device
160 rst steps have been reported with respect to
proof-
of-concept cardiovascular therapeutic applications
161 n by ultrasound cavitation was assessed in a
proof-
of-concept clinical trial in 12 subjects with stab
162 immune system, our results suggest that this
proof-
of-concept could potentially be utilized to reduce
163 This pilot study provides not only
proof-
of-concept data on the work impairment collected w
164 This
proof-
of-concept dynamic NA method is an extension of a
165 As a
proof-
of-concept example, we conducted theoretical evalu
166 Our
proof-
of-concept experiments show that multiple desired
167 atient-derived xenografts (zPDX) and provide
proof-
of-concept experiments that compare response to ch
168 These data provide a
proof-
of-concept for a new disease mechanism involving t
169 This study serves as a
proof-
of-concept for a new strategy for chemical imaging
170 We present here a
proof-
of-concept for bisphenol A detection; the device c
171 These results contribute to
proof-
of-concept for enhanced ethanol ablation as a nove
172 rent design considerations are explored, and
proof-
of-concept for highly pathogen-specific cargo rele
173 calable to microwell formats, and we provide
proof-
of-concept for its use in testing entry inhibitors
174 Here, we describe a
proof-
of-concept for new methodology to detect and quant
175 antitumor efficiency by FF conjugates and a
proof-
of-concept for new photosensitizer carriers based
176 Here, we provide
proof-
of-concept for the TFT, by showing that introducti
177 Our results constitute a
proof-
of-concept for, to our knowledge, a new design pri
178 A
proof-
of-concept gas sensor equipped with the resulting
179 Together these data provide
proof-
of-concept genetic evidence that blocking the clat
180 Proof-
of-concept has been established in nonhuman primat
181 Data from this
proof-
of-concept implementation is fit by a proposed mod
182 In a
proof-
of-concept in vivo experiment, blockade of C1q and
183 is designed and fabricated to demonstrate a
proof-
of-concept integrated device, which features wirel
184 Moreover, to move beyond
proof-
of-concept into translational applications, we dis
185 A
proof-
of-concept is demonstrated by an immunospecific de
186 tive ion detectors are used to demonstrate a
proof-
of-concept low-cost, amplifier-free, light-emittin
187 Limited
proof-
of-concept monotherapy studies to evaluate safety
188 We fabricated and tested a
proof-
of-concept NanoThermoMechanical device that has sh
189 This
proof-
of-concept of a membrane-free battery has an open
190 We provide
proof-
of-concept of Homo-PROTACs using diverse molecules
191 These results offer
proof-
of-concept of how the covalent conjugation of two
192 These findings represent
proof-
of-concept of the efficacy and tolerability of ant
193 We performed a
proof-
of-concept phase Ib study of ibrutinib monotherapy
194 To conduct a
proof-
of-concept pilot study of a wireless, patient-cent
195 In this
proof-
of-concept pilot study, patients wore wristband pe
196 Additionally, a
proof-
of-concept prototype system, which integrates an o
197 In a
proof-
of-concept setting systemic treatment with ustekin
198 ts that potentially influence the host, many
proof-
of-concept studies have demonstrated causative rol
199 In our recent article, we elaborate our
proof-
of-concept studies of a mouse/human chimeric IgE a
200 routine care in non-randomised, exploratory
proof-
of-concept studies.
201 mphasis on mechanistic advances and clinical
proof-
of-concept studies.
202 This
proof-
of-concept study demonstrates the feasibility of a
203 discovery of gammadelta T cells >30 y ago, a
proof-
of-concept study has not been done to prove the pr
204 Overall, this
proof-
of-concept study illustrates an efficient, general
205 Conclusion This
proof-
of-concept study indicates that TA of nonenhanced
206 Collectively, this
proof-
of-concept study links urine peptidomics to molecu
207 of the peripheral nervous system in MS, this
proof-
of-concept study may offer new insights into the p
208 This
proof-
of-concept study provides a new direction for regu
209 This
proof-
of-concept study sheds light on genotype-phenotype
210 This
proof-
of-concept study shows that the development of bot
211 A
proof-
of-concept study was conducted using T2 bacterioph
212 sed on a meta-Lasso regression model and the
proof-
of-concept study was performed using a large-scale
213 In this
proof-
of-concept study, Raman microspectroscopy was util
214 In this
proof-
of-concept study, stable isotope probing (SIP) was
215 In a
proof-
of-concept study, we defined two groups (1) an acu
216 In a
proof-
of-concept study, we enrolled 10 patients with lun
217 In a
proof-
of-concept study, we previously showed that colore
218 percutaneous nephrolithotomy (PCNL) in this
proof-
of-concept study.
219 In this study, we present a
proof-
of-concept technology comprising an on-chip planar
220 n actin polymerization in vitro As a further
proof-
of-concept test for cellular effects of these comp
221 We establish a
proof-
of-concept that a microtubule motor-cargo interfac
222 Proof-
of-concept that FFLUX's architecture is suitable f
223 Ultimately, our work demonstrates
proof-
of-concept that lentiviruses can be used for perma
224 Our data provide
proof-
of-concept that this technology can be used to tre
225 e laws of physics and has rapidly grown from
proof-
of-concept to robust demonstrations and deployment
226 , single-blind, randomised, sham-controlled,
proof-
of-concept trial.
227 d timing studies when rushing from promising
proof-
of-concept trials with surrogate end points such a
228 In this paper, we present a
proof-
of-concept validation experiment on top-view image
229 As
proof-
of-concept we investigated proteome-wide protein i
230 Herein, as a
proof-
of-concept, a family of dendrimers displaying inte
231 As
proof-
of-concept, a prototype platform is successfully u
232 As a
proof-
of-concept, the ability of niosomes to prevent phy
233 As a
proof-
of-concept, these materials were fabricated into t
234 As a
proof-
of-concept, this study demonstrates the successful
235 In addition to this
proof-
of-concept, use of PR scaffolds with differing phy
236 ancies have demonstrated compelling clinical
proof-
of-concept, validating the biology and drug discov
237 As
proof-
of-concept, we carry out field demonstrations wher
238 As a
proof-
of-concept, we delivered short guide RNAs targetin
239 As a
proof-
of-concept, we demonstrate the application of the
240 Using ABO blood typing as a
proof-
of-concept, we developed i) an integrated biologic
241 As a
proof-
of-concept, we have subjected the fourth generatio
242 For
proof-
of-concept, we propose an oxide-semiconductor-oxid
243 As an initial
proof-
of-concept, we used antibody-peptide fusions and f
244 As a
proof-
of-concept, we used these advances to rapidly muta
245 As
proof-
of-concept, we used this technology to treat mouse
246 validated the top 2 candidates in vivo as a
proof-
of-concept.
247 rst tested on a three-compartment phantom as
proof-
of-concept.
248 enhagen for the years 2016-2030 is used as a
proof-
of-concept.
249 ous targets, the progress on translating the
proof-
of-concepts to commercially viable and environment
250 istic 1,000 and 6,000 muatm exposures, and a
proof-
of-principle 30,000 muatm exposure.
251 We highlight a
proof-
of-principle and describe the working principle fo
252 me analysis by nanoLC-MS(2), and demonstrate
proof-
of-principle applications of the duplex and triple
253 Using this network, we perform a
proof-
of-principle demonstration of QDS mediated by MDI-
254 These data provide
proof-
of-principle evidence for the therapeutic potentia
255 Finally, we provide several
proof-
of-principle examples in which we model the effect
256 In a
proof-
of-principle experiment, treatment of these two su
257 This
proof-
of-principle experimental system allowed us to qua
258 Proof-
of-principle experiments demonstrated that in a ce
259 These
proof-
of-principle experiments show that the combination
260 In
proof-
of-principle experiments, we manipulated apterous,
261 In this article, we establish a
proof-
of-principle for methods to initiate and then moni
262 These data provide
proof-
of-principle for the view that newly generated ASC
263 nolysis of alpha-pinene has been chosen as a
proof-
of-principle model system.
264 on, gastric inhibitory polypeptide (GIP), as
proof-
of-principle peptides to demonstrate the value of
265 Based on these
proof-
of-principle results in healthy individuals, we pr
266 This
proof-
of-principle shows that specific enrichment of ele
267 ne therapy using AAV vectors and showed in a
proof-
of-principle study how this virus-host interaction
268 Our
proof-
of-principle study illustrates that transcriptome-
269 This
proof-
of-principle study introduces a sensing mechanism
270 In this physiologic
proof-
of-principle study, we determined whether transfus
271 To test this concept, in this-
proof-
of-principle study, we screened for modulators of
272 In our
proof-
of-principle study, we used comparative flow cytom
273 providing an excellent starting point for a
proof-
of-principle study.
274 Notably, we provide
proof-
of-principle that inhibiting IP3R3 degradation in
275 odels and human material provide preclinical
proof-
of-principle that validates uPA as a novel therape
276 We did a
proof-
of-principle trial with a novel endovascular baror
277 tis undergoing total knee replacement into a
proof-
of-principle trial.
278 We provide
proof-
of-principle under seminatural conditions for two
279 As our first
proof-
of-principle we employed the bacterial chemotaxis
280 As
proof-
of-principle, cell viability and immune responses
281 As a
proof-
of-principle, deoxynivalenol (DON), an important m
282 As a
proof-
of-principle, fluorophores containing a borinate (
283 In summary, these findings provide a
proof-
of-principle, rational strategy to target the MYB
284 For
proof-
of-principle, the clinically relevant glucagon-lik
285 As
proof-
of-principle, we conducted large-scale cell cycle
286 As a
proof-
of-principle, we explore the interactions of S. ce
287 To demonstrate
proof-
of-principle, we used the TRBO-sgRNA delivery plat
288 clinical studies have demonstrated promising
proofs-
of-concept, the performance of human clinical BCI
289 all exhibiting high R(2) values, serve as a
proof-
on-concept for the use of metabolic data for the d
290 Mutations of this motif directly modulate
proof-
reading by eliminating or enhancing selectivity fo
291 Here, we directly monitor RNA
proof-
reading by RIG-I and we show that it is controlled
292 It has been suggested that RIG-I has a '
proof-
reading' mechanism for rejecting host RNA targets,
293 [Note added in
proof:
Since the writing of this article, a fourth biosi
294 Criminal convictions require
proof that a prohibited act was performed in a statutori
295 In this work, we sought definitive
proof that dicarboxylic acids are produced in diesel eng
296 s to promote phenotype switching and provide
proof that targeting tumour cell plasticity is a viable
297 and then asthma, there is yet no definitive
proof that the atopic march is the primary causal factor
298 icroorganism is commonly used in industry to
proof the sterilization efficiency.
299 41 SSNs confirmed with surgically pathologic
proof were retrospectively reviewed.
300 This work presents the experimental
proof which validates the hypothesis of a pH change duri